Skip to content
How promising is Remdesivir? episode artwork

Nov 19, 2020 14 min

How promising is Remdesivir?

from Coronavirus: The Latest

Over a year since the first recorded case of Covid-19 in humans, only one antiviral drug is approved for its treatment. The Telegraph’s Global Health Security team speak to Dr Michael Elliot, Vice President of Medical Affairs at Gilead Sciences, the company that manufactures Remdesivir. They discuss how useful it is, whether big pharma is solely driven by profit and the prognosis for severe coronavirus sufferers in the second wave. Read more on the Oxford vaccine: https://bit.ly/2UVfPet | Read more on Brexit talks: https://bit.ly/36V8f8Y | Read more on the new quarantine-free list: https://bit.ly/3lMs88H | For 30 days' free access to The Telegraph: https://www.telegraph.co.uk/audio | Email: [email protected] |

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

How promising is Remdesivir?

0:00 14:34

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Coronavirus: The Latest?

This episode is 14 minutes long.

When was this Coronavirus: The Latest episode published?

This episode was published on November 19, 2020.

Can I download this Coronavirus: The Latest episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.